新辅助内分泌治疗后腋窝转移淋巴结中Ki-67蛋白表达对绝经后乳腺癌预后的影响  

Association Between Expression of Ki-67 in Axillary Lymph Nodes and Prognosis of Postmenopausal Breast Cancer Patients After Neoadjuvant Endocrine Therapy

作　　者：金一[1] 姜大庆[1] 马特[1] 王彪[2] 孟欣[2] 张海燕[3] 

机构地区：[1]中国医科大学肿瘤医院,辽宁省肿瘤医院,辽宁沈阳110042 [2]中国医科大学基础医学院生物化学与分子生物教研室,辽宁沈阳110122 [3]中国医科大学附属第一医院,辽宁沈阳110001

出　　处：《肿瘤学杂志》2016年第12期1042-1047,共6页Journal of Chinese Oncology

基　　金：国家自然科学基金项目(81572831)

摘　　要：[目的]探讨乳腺癌新辅助内分泌治疗后腋窝转移淋巴结中Ki-67蛋白的表达和患者预后的关系。[方法]回顾性分析108例新辅助内分泌治疗腋窝转移淋巴结乳腺癌患者的临床和病理资料。结果 108例患者中,术后淋巴结Ki-67蛋白〉10%者71例,Ki-67≤10%者37例。全组中位随访40个月,其中Ki-67≤10%组和Ki-67〉10%组无病生存率分别为83.8%,54.9%,差异有统计学意义（P=0.004）;总生存率分别为91.9%和71.8%,差异有统计学意义（P=0.019）。COX多因素分析的结果显示,术后腋窝淋巴结Ki-67蛋白表达的状态是影响患者无病生存和总生存的主要因素（RR=0.300,95%CI为0.125-0.718,P=0.007;RR=0.260,95%CI为0.077~0.876,P=0.030）。[结论]新辅助内分泌治疗后腋窝淋巴结Ki-67蛋白表达的高低是预测乳腺癌患者预后的有效指标。[Objective] To investigate the association between expression of Ki-67 in axillary lymph nodes and prognosis in postmenopausal breast cancer patients after neoadjuvant endocrine therapy. [Methods] The clinical and pathological data of 108 postmenopausal breasts cancer patients who underwent neoadjuvant endocrine therapy were analyzed retrospectively. [Results] The median follow up time was 40 months. Among 108 patients the expression of Ki-67 in axillary lymph nodes was 10% in 71 cases and expression of Ki-67 was ≤10% in 37 cases. The disease free survival（DFS） in the two groups was 54.9% and 83.8%（P=0.004）,the overall survival（OS）was 71.8% and 91.9%（P =0.019）,respectively. The multivariate analysis indicated that the expression of Ki-67 in axillary lymph nodes was an independent prognostic factor for DFS and OS（RR=0.300,95%CI：0.125-0.718,P=0.007;RR=0.260,95%CI：0.077-0.876,P =0.030）. [Conclusion] The expression of Ki-67 in axillary lymph nodes is an effective indicator for predicting the prognosis of postmenopausal breast cancer patients after neoadjuvant endocrine therapy.

关 键 词：新辅助内分泌治疗 腋窝淋巴结 KI-67 预后 乳腺肿瘤 

分 类 号：R737.9[医药卫生—肿瘤]